Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance.

about

Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance.

Item

http://www.wikidata.org/entity/Q55496875

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Crosstalk between ERα and Rece ...... of Anti-Endocrine Resistance.

@en

Crosstalk between ERα and Rece ...... of Anti-Endocrine Resistance.

@nl

type

Item

label

Crosstalk between ERα and Rece ...... of Anti-Endocrine Resistance.

@en

Crosstalk between ERα and Rece ...... of Anti-Endocrine Resistance.

@nl

prefLabel

Crosstalk between ERα and Rece ...... of Anti-Endocrine Resistance.

@en

Crosstalk between ERα and Rece ...... of Anti-Endocrine Resistance.

@nl

P1476

Crosstalk between ERα and Rece ...... of Anti-Endocrine Resistance.

@en

P2093

Helen M Coley

http://www.w3.org/2001/XMLSchema#string

Rugaia Z Montaser

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Hallmarks of Cancer: The Next Generation

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells

Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.

Aromatase inhibitors for breast cancer: lessons from the laboratory.

P31

scholarly article

P356

10.3390/CANCERS10060209

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29925812

http://www.w3.org/2001/XMLSchema#string

P932

6025235

http://www.w3.org/2001/XMLSchema#string